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Objectives: to determine the risk of rupture in patients with large non-operated abdominal aortic aneurysms (AAAs).
Methods: in 128 patients admitted over a 5-year period with an intact AAA, and who did not have a surgical repair were
included, initial maximum antero-posterior AAA diameter was related to survival and cause of death.
Results: at the end of follow-up 27/52 (52%) patients with AAA ,55 mm were alive compared to 17/62 (27%) patients
with AAA $55 mm. Six (12%) in the former and 18 (29%) in the latter group had an AAA-related death. However, non-
AAA-related death was commoner in both groups.
Conclusion: these findings support a role for non-operative management in high-risk patients with large AAAs.
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Introduction
An abdominal aortic aneurysm (AAA) should only be
repaired if the risks of rupture outweigh the risk of
surgery. Unfortunately, despite technical and anaes-
thetic advances, the operative mortality associated
with elective AAA repair has changed little over the
last 10–20 years. Furthermore, randomised controlled
trial (RCT) data indicate that, as the risk of rupture for
small AAA (,55 mm) is significantly lower than
previously thought, there is no survival benefit from
surgery. The situation with regard to large AAA
$55 mm remains unclear as there are no RCT data
to show that surgery confer a survival benefit, as few
natural history studies exist.1 – 3 This study aimed to
assess the outcome for patients admitted with asymp-
tomatic and symptomatic AAAs who were considered
too unfit for operative intervention.
Method
All patients admitted with non-rupture AAA between
January 1995 and December 1999 were identified by
interrogating a prospectively gathered database.
Survival data were obtained from hospital and general
practice records. Cause and date of death were
obtained from the General Register Office for Scotland.
Patients were classified as asymptomatic or sympto-
matic AAA and by initial maximum antero-posterior
diameter on ultrasonography (,55 and $55 mm).
Symptomatic and asymptomatic AAA $55 mm were
assessed for surgery by both a consultant vascular
anaesthetist and surgeon on the basis of co-morbidity
and patient wishes. All patients underwent full clinical
examination, electrocardiography, trans-thoracic
echocardiography, pulmonary function tests and
assessment of exercise tolerance. Exercise electrocar-
diography, dobutamine stress echocardiography and
coronary angiography were used selectively. Endo-
vascular aortic replacement was not employed rou-
tinely at this time. Statistical analysis was performed
using SPSS for Windows Release 11.0.0. Kaplan–Meier
life tables were used to calculate survival and
compared using the log rank test; p # 0:05 was
considered significant.
Results
In the study period, 758 AAA patients were admitted
of which 457 were intact. Of these, 329 underwent
surgical repair and 128 did not. The latter group
comprised 77 men and 51 women of median (range)
age 73 (60–92) years, and 75 (59%) patients were
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asymptomatic. The median (range) AAA diameter
was 55 (27–85) mm for asymptomatic and 55 (33–
100) mm for symptomatic patients. Fifty-two (46%) of
114 patients had an AAA of,55 mm, 62 (54%) a lesion
of $55 mm, and 46 (40%) a lesion of $60 mm.
Significant cardiac disease, the commonest reason for
non-operative management, was noted in 49 (38%)
patients (Table 1). Thirty (23%) patients had a small
aneurysm that was asymptomatic or had symptoms
that resolved.
Follow-up was complete for 125 (98%) patients.
Eleven patients had imprecise initial sizing of their
AAA. Median (range) overall follow-up was 19 (1–74)
months; mean follow-up was 23 months. At the end of
follow-up 76 (61%) of 125 patients had died and 49
(39%) were still alive. Of the 30 patients in whom open
AAA repair was deferred due to small aneurysm size
only four went on to undergo surgical repair during
the follow-up period.
At the end of the study, in the asymptomatic
group 31 (43%) of 72 patients were still alive,
compared to 18 (34%) of 53 patients in the sympto-
matic group. For patients with aneurysms ,55 mm in
diameter, 27 (52%) were still alive; 17 (27%) of those
with aneurysms $55 mm in diameter were alive. In
the ,55-mm group, only six (12%) patients had an
AAA related death; in the $55-mm group 18 (29%)
had a death attributed to AAA (Tables 2 and 3).
Including patients for whom accurate sizing was
unavailable, only 27 (22%) of 125 had a death related
to AAA. Of these 27 patients, all but one patient who
declined surgery were deferred due to prohibitive
co-morbidity. Deaths from other causes were most
often attributed to cardiac disease (14 patients),
respiratory disease (14 patients) and malignancy
(eight patients) (Table 4).
In patients with an aneurysm ,55 mm in diameter
the cumulative survival at one year was 84 and 65% for
asymptomatic and symptomatic lesions respectively
ðp , 0:05Þ: In patients with aneurysms $55 mm in
diameter the cumulative survival at one year was 42
and 52% for asymptomatic and symptomatic lesions
respectively ðp ¼ 0:30Þ: Cumulative one year survival
for patients with aneurysms ,55 mm and those with
lesions $55 mm in diameter was 77 and 48%
respectively ðp , 0:005Þ: Overall cumulative survival
at one year was 62% and median survival time was 27
months (Figs. 1–3).
Table 1. Reason for no operation in 128 patients.
Reason for refusal Number
(%)
Cardiac disease 49 (38)
Small aneurysm 30 (23)
Malignant disease 14 (11)
Others (dementia, chronic renal failure, gastrointestinal) 11 (9)
Thoracoabdominal aneurysm 9 (7)
Advanced age 8 (6)
Patient declined 7 (5)
Table 2. Outcomes of asymptomatic and symptomatic AAA.
Size ,55 mm Size $55 mm
Asymptomatic Symptomatic Asymptomatic Symptomatic
Number of patients 32 20 33 29
Median follow-up (range) in months 30 (1–73) 20 (1–74) 8 (1–41) 19 (1–52)
AAA related death 4 2 9 9
Other cause of death 8 11 15 12
Total deaths 12 13 24 21
Median follow-up (range) months 27 (1–55) 8 (1–41) 6 (1–40) 7 (1–50)
Alive 20 7 9 8
Median follow-up (range) months 40 (19–73) 32 (17–74) 24 (19–41) 33 (25–52)
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Fig. 1. Survival free of rupture: all aneurysms.
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Discussion
Few other contemporary studies of AAA natural
history exist to inform any prediction of outcome in
non-operated patients. Clearly, a randomised con-
trolled population based study represents the ideal
model for such an analysis but the difficulties in
performing such a trial are formidable. In the present
series 28% of patients admitted for assessment were
deemed unsuitable for, or declined, surgery. This is
similar to the 1970 figures of Szilagyi and colleagues
who found 24% of patients were turned down for
surgery.4 It might have been anticipated that improve-
ments in peri-operative care would have lowered the
threshold for offering open surgical repair but this is
not supported by present data. This is likely to be a
reflection of a greater number of patients with
significant comorbidity being referred for assessment.
For AAAs ,55 mm in diameter, 48% of patients
Table 3. Outcome of large aneurysms.
55–59 mm 60–69 mm $70 mm
Number of patients 16 28 18
Median follow-up (range) in months 19 (3–45) 21 (1–52) 8 (1–38)
AAA related death 3 9 6
Other cause of death 8 11 8
Total deaths 11 20 14
Median follow-up (range) months 9 (3–46) 7 (1–50) 7 (1–35)
Alive 5 8 4
Median follow-up (range) months 41 (19–47) 27 (23–52) 26 (23–38)
Table 4. Causes of death.
Cause of death Size ,55 mm Size ,55 mm Total
Asymptomatic Symptomatic Asymptomatic Symptomatic
AAA rupture 4 2 9 9 24
Cardiac 2 4 5 3 14
Respiratory 1 2 8 3 14
Malignancy 3 3 0 2 8
Gastro-intestinal 1 2 2 0 5
Other 1 0 0 4 5
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had died at the end of follow up. In this group only
12% had a death related to their aortic lesion, a non-
AAA death to AAA death ratio of 3:1. This represents
a greater rupture rate than the 1% reported by the U.K.
Small Aneurysm Trial.1 All patients had prohibitive
medical co-morbidity and it remains unclear whether
such patients are at a higher risk of AAA rupture than
their healthier peers. Similar findings were, however,
noted in an analysis of high-risk patients in the U.K.
Small Aneurysm Trial and in a recent study by Lederle
et al.5 In any event, a non-AAA related cause of death
remained three times more likely and these data
generally support the conclusion of the U.K. Small
Aneurysm Trial that small aneurysms tend to follow a
benign course.
For AAA $55 mm in diameter, 73% of patients had
died at the end of follow up. Overall, 29% had an AAA
related death and 44% a non-AAA related death.
Conway et al. reported that 49% of deaths could be
attributed to ruptured AAA in non-operated large
aneurysms.3 Eighteen percent of their aneurysms were
,60 mm compared to 26% in the present cohort of
large aneurysms. More recently Tanquilut et al.
reported their experience of selective delayed surgery
for large AAA in high risk patients. Of 19 patients
treated solely non-operatively 47% died of a non-AAA
related cause while only 16% had a death attributable
to AAA.6 Clearly, large aneurysms are prone to a
significant rate of rupture but, once again, an
alternative cause of death was more common in the
current series.
These data describe an uncontrolled series with
relatively small numbers; the limitations of using
death certificate records to ascertain cause of death are
also recognised. Nevertheless, the present data man-
date careful patient selection for intervention. While
one might argue that surgery can prevent death from
AAA rupture, the operative risk in these patients
would have been extremely high. Recent reports from
the EUROSTAR collaborators have suggested a poss-
ible role for endovascular aortic replacement in this
setting; the results of the EVAR I and II trials should
shed further light on this contentious issue.7,8 It is
interesting to note that median AAA diameter in the
EUROSTAR series is 56 mm.9
The natural history of AAA remains unclear. The
present series tends to support a cautious approach to
small AAAs. High-risk large AAAs may be best
treated by EVAR but the evidence thus far is not
conclusive.
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